OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company focused on neuropathic corneal pain and anterior segment eye diseases, has announced it will participate in the 2026 Jefferies Global Healthcare Conference in London from 16 to 19 November 2026. The company's leadership team will be available for one-on-one investor meetings throughout the four-day event. The appearance follows a notable pipeline milestone: OKYO recently announced that first patients have been enrolled in the Phase 3 NEPTUNE trial of its lead candidate, urcosimod, for neuropathic corneal pain.

Key Points

  • OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company listed on the Nasdaq Capital Market
  • OKYO will participate in the 2026 Jefferies Global Healthcare Conference in London, running from 16 to 19 November 2026
  • First patients have been enrolled in the Phase 3 NEPTUNE trial of lead candidate urcosimod for neuropathic corneal pain
  • Investors should watch for updates arising from one-on-one meetings with OKYO's leadership team at the conference

OKYO Pharma Heads to Jefferies London Conference with Phase 3 NEPTUNE Trial Under Way

OKYO Pharma's participation in the Jefferies Global Healthcare Conference places the company in front of a significant international investor audience at a strategically important moment. The company's lead asset, urcosimod, is an investigational therapy targeting neuropathic corneal pain, a condition affecting the anterior segment of the eye. With first patients now enrolled in the Phase 3 NEPTUNE trial, the company enters the conference at a stage where clinical momentum may attract heightened institutional interest. The Jefferies event runs across four days in London and brings together global healthcare investors and biopharmaceutical companies.

Urcosimod and the Phase 3 NEPTUNE Trial: OKYO's Lead Programme for Neuropathic Corneal Pain

Urcosimod is OKYO Pharma's most advanced investigational compound, developed specifically to address neuropathic corneal pain, an underserved condition within the broader anterior segment eye disease space. The announcement confirms that first patients have been enrolled in the Phase 3 NEPTUNE trial, representing a meaningful step forward in the clinical development timeline. Neuropathic corneal pain currently has limited approved treatment options, which the company positions as a potential commercial opportunity. The company did not disclose trial size, expected completion dates, or financial metrics in this announcement.

One-on-One Investor Meetings Available Throughout the Four-Day London Event

OKYO Pharma's leadership team will be accessible for individual investor meetings across the duration of the Jefferies Global Healthcare Conference. The announcement states that investors wishing to arrange a meeting should contact their Jefferies representative directly. This format is typical for clinical-stage companies seeking to build relationships with institutional investors and analysts ahead of key data readouts. The company is listed on the Nasdaq Capital Market and maintains offices in both London and New York, reflecting its dual transatlantic presence and investor base.